What SEC filings does Kailera Therapeutics, Inc. submit to the SEC?

Kailera Therapeutics, Inc. (KLRA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about KLRA?

A Form 4 for KLRA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Kailera Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for KLRA?

The 10-K is Kailera Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all KLRA SEC filings directly on EDGAR?

You can view all historical Kailera Therapeutics, Inc. filings on the SEC EDGAR company page for KLRA. Each filing card on this page links directly to the original SEC document.

How often does Kailera Therapeutics, Inc. file with the SEC?

Kailera Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling KLRA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

KLRA SEC Filing News — Kailera Therapeutics, Inc.

Latest SEC filings for Kailera Therapeutics, Inc. (KLRA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-09.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-ag…

Sector: Healthcare Industry: Biotechnology Market Cap: $1.5B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for KLRA currently lean bullish. Of the 20 displayed SEC filing records, 5 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 16 insider transactions (Form 4) in this period.

KLRA Filing Activity Snapshot 2026-04-20 — 2026-09-09

Insider Transactions (Form 4)

5 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$134.38M

BAIN CAPITAL INVESTORS LLC (10% Owner) · 2026-04-20

8,398,438 shares · Form 4

Insider Transactions 16 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 16 filings in this group are Form 4s for Kailera Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 16 insider filings shown, the breakdown is 9 compensation award, 5 open-market purchase, 1 derivative conversion and 1 option exercise. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×5: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Derivative conversion ×1: A derivative security was converted into common stock under terms agreed earlier.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Compensation award Tax / Compensation Filing 2026-09-09

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Nicholson Nur (Chief Technology Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	220,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Nicholson Nur (Chief Technology Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-08

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Tregoning Kathleen (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	175,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Tregoning Kathleen (See Remarks)

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-06-11

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Renaud Ronald C JR (Director, CEO & President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	38,094	$5.25	$200.0K
`M`	Option exercise derivative · Stock Option (right to buy)	38,094	—	—

Filing: Form 4 (Insider Transaction) Insider: Renaud Ronald C JR (Director, CEO & President) Shares: 38,094

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-22

KLRA insider RTW INVESTMENTS, LP (10% Owner) bought 500,000 shares (~$8.00M)

RTW INVESTMENTS, LP, listed as 10% Owner at Kailera Therapeutics, Inc., reported an open-market purchase of 500,000 KLRA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	10,276,820	—	—
`P`	Open-market purchase	500,000	$16.00	$8.00M
`C`	Derivative conversion derivative · Series A Preferred Stock	8,250,000	—	—
`C`	Derivative conversion derivative · Series B Preferred Stock	2,026,820	—	—

Filing: Form 4 (Insider Transaction) Insider: RTW INVESTMENTS, LP (10% Owner) Shares: 500,000 Est. Value: $8.00M

View on SEC EDGAR → Open Filing Document →

Form 4 Derivative conversion Tax / Compensation Filing 2026-04-22

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

A derivative security was converted into common stock under terms agreed earlier.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	9,477,719	—	—
`C`	Derivative conversion	2,034,133	—	—
`C`	Derivative conversion derivative · Series A-2 convertible preferred stock	4,968,789	—	—
`C`	Derivative conversion derivative · Series A-2 convertible non-voting preferred stock	708,814	—	—

Filing: Form 4 (Insider Transaction) Insider: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (10% Owner) Shares: 11,511,852

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

KLRA insider BAIN CAPITAL INVESTORS LLC (10% Owner) bought 8,398,438 shares (~$134.38M)

BAIN CAPITAL INVESTORS LLC, listed as 10% Owner at Kailera Therapeutics, Inc., reported an open-market purchase of 8,398,438 KLRA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	17,857,143	—	—
`P`	Open-market purchase	8,398,438	$16.00	$134.38M
`C`	Derivative conversion derivative · Series B Preferred Stock	17,857,143	—	—

Filing: Form 4 (Insider Transaction) Insider: BAIN CAPITAL INVESTORS LLC (10% Owner) Shares: 8,398,438 Est. Value: $134.38M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

KLRA insider Koppel Adam (Director, 10% Owner) bought 1,562,500 shares (~$25.00M)

Koppel Adam, listed as Director, 10% Owner at Kailera Therapeutics, Inc., reported an open-market purchase of 1,562,500 KLRA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	16,875,000	—	—
`C`	Derivative conversion	4,145,768	—	—
`P`	Open-market purchase	1,562,500	$16.00	$25.00M
`C`	Derivative conversion derivative · Series A-1 Preferred Stock	16,875,000	—	—
`C`	Derivative conversion derivative · Series B Preferred Stock	4,145,768	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	38,300	—	—

Filing: Form 4 (Insider Transaction) Insider: Koppel Adam (Director, 10% Owner) Shares: 1,562,500 Est. Value: $25.00M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

KLRA insider Bain Capital Life Sciences Investors, LLC (10% Owner) bought 1,562,500 shares (~$25.00M)

Bain Capital Life Sciences Investors, LLC, listed as 10% Owner at Kailera Therapeutics, Inc., reported an open-market purchase of 1,562,500 KLRA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	16,875,000	—	—
`C`	Derivative conversion	4,145,768	—	—
`P`	Open-market purchase	1,562,500	$16.00	$25.00M
`C`	Derivative conversion derivative · Series A-1 Preferred Stock	16,875,000	—	—
`C`	Derivative conversion derivative · Series B Preferred Stock	4,145,768	—	—

Filing: Form 4 (Insider Transaction) Insider: Bain Capital Life Sciences Investors, LLC (10% Owner) Shares: 1,562,500 Est. Value: $25.00M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-20

KLRA insider Kaplan Andrew T. (Director, 10% Owner) bought 8,398,438 shares (~$134.38M)

Kaplan Andrew T., listed as Director, 10% Owner at Kailera Therapeutics, Inc., reported an open-market purchase of 8,398,438 KLRA shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`C`	Derivative conversion	17,857,143	—	—
`P`	Open-market purchase	8,398,438	$16.00	$134.38M
`C`	Derivative conversion derivative · Series B Preferred Stock	17,857,143	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	38,300	—	—

Filing: Form 4 (Insider Transaction) Insider: Kaplan Andrew T. (Director, 10% Owner) Shares: 8,398,438 Est. Value: $134.38M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Cloghessy Paula (Chief People Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	60,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Cloghessy Paula (Chief People Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Akamine Scott (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	60,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Akamine Scott (Chief Legal Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	300,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	300,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Renaud Ronald C JR (Director, CEO & President)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Burgess Paul D. (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	100,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	100,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Burgess Paul D. (See Remarks)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

MILLIGAN JOHN F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	38,300	—	—

Filing: Form 4 (Insider Transaction) Insider: MILLIGAN JOHN F (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

Coleman Jamie Beth (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	75,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	75,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Coleman Jamie Beth (Chief Commercial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-20

KLRA insider Form 4 filed for equity award, exercise, or tax withholding

MACKAY MARTIN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	38,300	—	—

Filing: Form 4 (Insider Transaction) Insider: MACKAY MARTIN (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Kailera Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-12

KLRA filed 8-K — material company event

Kailera Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-26

KLRA filed 8-K — material company event

Kailera Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 quarterly reports (10-Q) for Kailera Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-12

KLRA filed Quarterly Report (10-Q)

Kailera Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-26

KLRA filed Quarterly Report (10-Q)

Kailera Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Kailera Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on KLRA. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — KLRA SEC Filings

More Tools for KLRA

KLRA Full Stock Analysis KLRA Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper KLRA analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the KLRA stock analysis page.

KLRA Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer